Investors
Verona Pharma (Nasdaq: VRNA) is focused on developing and commercializing innovative life-enhancing treatments for chronic respiratory diseases. Our first-in-class product, OhtuvayreTM (ensifentrine), is approved in the US for the maintenance treatment of COPD. The Company is led by an experienced management team with an established track record in the discovery, clinical development and commercialization of respiratory therapeutics.
16.99 USD
View our latest presentation
Explore our recent results
LONDON and RALEIGH, N.C., July 25, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the second quarter ended June 30, 2024 on Thursday, August 8, 2024 and host an investment community conference call
Ohtuvayre is indicated for the maintenance treatment of COPD allowing for broad use in COPD patients First inhaled COPD treatment providing bronchodilation and non-steroidal anti-inflammatory effects Conference call tomorrow at 8:30 a.m. EDT / 1:30 p.m.
PDUFA Target Action Date for Ensifentrine of June 26, 2024 Finalizing commercial launch preparations Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT /…
Non-dilutive funding will support planned US commercial launch and expansion of ensifentrine’s clinical activities Cash runway extended beyond 2026 LONDON and RALEIGH, N.C., May 09, 2024 (GLOBE NEWSWIRE) — Verona Pharma…
PDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of ensifentrine, an investigational, first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and…
Aug
08
2024
09:00 AM EST
14:00 PM BST
Jun
27
2024
May
09
2024
Verona Pharma (Nasdaq:VRNA) is focused on delivering our strategy and creating value for shareholders.
